Internship

Intern – Corporate Affairs

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$22 - $45Hourly

San Bruno, CA, USA

Paid internship at South San Francisco headquarters.

Category
Public Health
Biology & Biotech
Required Skills
Communications
Social Media
Marketing
Requirements
  • Currently enrolled undergraduate or graduate student or recent graduate with bachelor’s degree in public relations, marketing, communications or related field
  • Experience and/or passion for communications, public relations, investor relations, patient advocacy or professional society relations
  • Basic knowledge of healthcare industry and strong interest in biotech and/or nonprofit patient organizations
  • Excellent written and verbal communications skills and understanding of AP Style
  • A good multi-tasker, detail oriented and resourceful
  • Well-versed in Microsoft Office Suite
Responsibilities
  • Developing social media content for social media channels and internal communication channels
  • Tracking investor interactions using an online database
  • Developing investor and firm profiles
  • Participating in Investor Relations event planning
  • Supporting event planning for disease awareness and advocacy activities
  • Developing articles for the internal company blog
  • Supporting internal communications activities
  • Supporting coordination of patient advocacy events
  • Providing advocacy operations support including database and calendar updates and tracking
  • Creating reports on nonprofit patient advocacy partner programs
  • Conducting patient advocacy-related research as assigned
  • Conducting ad hoc research and administrative projects across corporate communications, investor relations, patient advocacy and professional society relations as necessary

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, depending on the condition being treated. For example, they are working on drugs for heart failure, hypertrophic cardiomyopathy, amyotrophic lateral sclerosis, and spinal muscular atrophy. What sets Cytokinetics apart from competitors is their specific focus on muscle-related conditions and their extensive pipeline of drugs currently in clinical trials. The company's goal is to bring effective treatments to market that address the unmet needs of patients suffering from these debilitating diseases.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Phase III trial results for aficamten in treating obstructive hypertrophic cardiomyopathy (HCM) highlight the company's potential for market leadership in this area.
  • The $575M funding from Royalty Pharma ensures strong financial support for the commercial launch of aficamten and further R&D activities.
  • Recent investments and stock offerings indicate strong investor confidence and provide additional capital for growth and development.

What critics are saying

  • The late-stage biopharmaceutical market is highly competitive, with significant pressure to bring drugs to market quickly and efficiently.
  • Dependence on the success of clinical trials and regulatory approvals poses inherent risks, as any setbacks could delay commercialization and revenue generation.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle function improvement for cardiovascular and neuromuscular diseases, a niche area with high unmet medical needs.
  • The company has a robust pipeline of small molecule muscle activators and inhibitors, setting it apart from competitors with more generalized drug portfolios.
  • Strategic funding collaborations, such as the $575M deal with Royalty Pharma, provide significant financial backing for their R&D and commercialization efforts.

Help us improve and share your feedback! Did you find this helpful?